(2S,3S,4S,5R,6S)-6-[[(3R,5R)-3-butyl-3-ethyl-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4S,5R,6S)-6-[[(3R,5R)-3-butyl-3-ethyl-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• 英文别名: (2S,3S,4S,5R,6S)-6-[[(3R,5R)-3-butyl-3-ethyl-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1λ6,4-benzothiazepin-8-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
• 化学式: C₂₇H₃₅NO₉S
• 分子量: 549.6
• InChiKey: VIYXPTCOEMGRJL-KORGWXJCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  171
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• Therapeutic agents
  申请人：Alstermark Lindstedt Eva-Lotte

  公开号：US20050282822A1

  公开（公告）日：2005-12-22

  The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  本发明提供了一种I式化合物，以及制备这种化合物的方法，它们在治疗临床病症中的应用，包括与胰岛素抵抗有关的脂质紊乱（脂质代谢异常），以及它们的治疗用途和含有它们的药物组合物。
• Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
  申请人：Starke Ingemar

  公开号：US20050239766A1

  公开（公告）日：2005-10-27

  Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了公式(I)的化合物：(其中变量基团的定义如下)、药学上可接受的盐、该盐的溶剂合物、该盐的溶剂合物的前药及其用作治疗高血脂症的胆固醇吸收抑制剂的用途。还描述了它们的制造过程和含有它们的制药组合物。
• Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance
  申请人：Li Lanna

  公开号：US20050256198A1

  公开（公告）日：2005-11-17

  The present invention provides a compound of formula (I), wherein n is 0, 1 or 2 and R 1 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents R 1 may be the same or different; R 2 represents a C 2-8 alkyl group which is optionally interrupted by oxygen; Y is absent or represents methylene; and X is O or S; and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明提供了式(I)的化合物，其中n为0、1或2，R1代表卤素、C1-4烷基，该烷基可选地被一个或多个氟取代，C1-4烷氧基，该烷氧基可选地被一个或多个氟取代，当n为2时，取代基R1可以相同也可以不同；R2代表C2-8烷基，该烷基可选地被氧中断；Y不存在或代表亚甲基；X为O或S；以及其药学上可接受的盐和前药，制备这种化合物的方法，它们在治疗与胰岛素抵抗有关的临床病症方面的用途，以及包含它们的制药组合物的方法。
• Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
  申请人：Lindstedt Alstermark Eva-Lotte

  公开号：US20050113362A1

  公开（公告）日：2005-05-26

  The present invention provides the S enantiomer of a compound of formula (I); wherein R 1 represents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明提供了式(I)化合物的S对映体;其中R1代表2,4-二氟苯基或环己基，以及其药学上可接受的盐、溶剂化合物、晶体形式和前药，以及制备这些化合物的方法，它们在治疗包括脂质紊乱（失调脂质症）在内的临床疾病方面的效用，无论是否与胰岛素抵抗有关，以及用于它们的治疗方法和包含它们的制药组合物。
• Carboxylic derivates
  申请人：Li Lanna

  公开号：US20050148656A1

  公开（公告）日：2005-07-07

  The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  本发明提供了一种I式化合物，以及制备这些化合物的方法，它们在治疗临床情况（包括是否与胰岛素抵抗有关的脂质紊乱）方面的效用，以及它们的治疗用途和含有它们的制药组合物。